Southpoint reports 0% stake in Fennec Pharma
Fennec Pharmaceuticals Inc. received an amended Schedule 13G (Amendment No. 3) from a group of Southpoint-related entities and individual John S. Clark regarding its Common Shares, no par value.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Fennec Pharmaceuticals Inc. received an amended Schedule 13G (Amendment No. 3) from a group of Southpoint-related entities and individual John S. Clark regarding its Common Shares, no par value. The reporting persons – Southpoint Master Fund, LP; Southpoint Capital Advisors LP; Southpoint Capital Advisors LLC; Southpoint GP, LP; Southpoint GP, LLC; and John S. Clark – each report 0 Common Shares beneficially owned, with 0% of the class and no sole or shared voting or dispositive power. They indicate they now hold ownership of 5 percent or less of the class. The filing is signed by John S. Clark II in multiple related capacities on August 14, 2026.
Key Figures
Key Terms
beneficially owned financial
sole voting power financial
Ownership of 5 percent or less of a class regulatory
Schedule 13G regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does Southpoint’s Schedule 13G/A filing mean for FENC?
What percentage of Fennec Pharmaceuticals (FENC) does Southpoint now report?
Who are the reporting persons in this FENC Schedule 13G/A amendment?
When was the Southpoint Schedule 13G/A for FENC signed and as of what date is it reported?
AI-generated analysis. How Rhea-AI works. Not financial advice.